New Strategy Targets Common Cancer Driver with Minimal Side Effects

Researchers at Weill Cornell Medicine have identified a common vulnerability across various cancer types, including colorectal and breast cancers. They are developing drug compounds aimed at exploiting this vulnerability, potentially leading to effective treatments with fewer side effects. This approach could benefit a wide range of cancer patients.

Originally published by gnews